Education
About Us
Working with TipRanks
Follow Us
Genprex (GNPX)
:GNPX
GNPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.14 - $3.97
Previous Close$0.82
Volume416.42K
Average Volume (3M)16.77M
Market Cap
$9.99M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.35
Shares Outstanding42,905,340
10 Day Avg. Volume35,433,695
30 Day Avg. Volume16,767,554
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genprex News
GNPX FAQ
What was Genprex’s price range in the past 12 months?
Genprex lowest stock price was $0.14 and its highest was $3.97 in the past 12 months.
What is Genprex’s market cap?
Genprex’s market cap is $9.99M.
When is Genprex’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genprex’s earnings last quarter?
Currently, no data Available
Is Genprex overvalued?
According to Wall Street analysts Genprex’s price is currently Overvalued.
Does Genprex pay dividends?
Genprex does not currently pay dividends.
What is Genprex’s EPS estimate?
Genprex’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genprex have?
Genprex has 42,905,340 shares outstanding.
What happened to Genprex’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genprex?
Currently, no hedge funds are holding shares in GNPX
Company Description
Genprex
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex (GNPX) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Brainstorm Cell Therapeutics
―
GT Biopharma
―
Aptorum Group
―
Lyra Therapeutics
―
Conduit Pharmaceuticals
―
Ownership Overview
0.18% Insiders
0.24% Mutual Funds
0.23% Other Institutional Investors
98.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---